US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Devonian Health Group Inc.

0.0711

0.0000

Volume:- -

Turnover:- -

Market Cap:196.64K

PE:-0.04

High:0.0711

Open:0.0711

Low:0.0711

Close:0.0711

52wk High:10.80

52wk Low:0.0711

Shares:2.77M

Float Shares:2.12M

Volume Ratio:0.26

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9540

EPS(LYR):-0.3475

ROE:-59.92%

ROA:-4.59%

PB:0.03

PE(LYR):-0.20

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT

Press Release: Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update

Press Release: Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member

Press Release: Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DVHGF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DVHGF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DVHGF\",,,,,undefined,":{"symbol":"DVHGF","market":"US","secType":"STK","nameCN":"Devonian Health Group Inc.","latestPrice":0.0711,"timestamp":1771621200000,"preClose":0.0711,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":2117019,"shares":2765725,"eps":-1.95396,"marketStatus":"Market Closed","change":0,"latestTime":"02-20 16:00:00 EST Delay","open":0.0711,"high":0.0711,"low":0.0711,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.95396,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"exchange":"OTCQB","adjPreClose":0.0711,"volumeRatio":0.256865328366548},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DVHGF\",,,,,undefined,":{"symbol":"DVHGF","floatShares":2117019,"roa":"-4.59%","roe":"-59.92%","lyrEps":-0.34752,"volumeRatio":0.256865328366548,"shares":2765725,"dividePrice":0,"high":0.0711,"amplitude":0,"preClose":0.0711,"low":0.0711,"week52Low":0.0711,"pbRate":"0.03","psRate":"0.01","week52High":10.8,"institutionHeld":0,"latestPrice":0.0711,"eps":-1.95396,"divideRate":0,"volume":0,"delay":15,"ttmEps":-1.95396,"open":0.0711,"prevYearClose":0.0711,"prevWeekClose":0.0711,"prevMonthClose":0.0711,"prevQuarterClose":0.0711,"fiveDayClose":0.0711,"twentyDayClose":0.0711,"sixtyDayClose":0.0711},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DVHGF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-22","symbol":"DVHGF","defaultRemindTime":1769092200000,"type":"split","dateTimestamp":1769058000000,"forFactor":60,"toFactor":1,"ratio":60},{"market":"US","date":"2024-12-23","symbol":"DVHGF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1734930000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-29","symbol":"DVHGF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1732856400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-06-25","symbol":"DVHGF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1719288000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-03-27","symbol":"DVHGF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711512000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DVHGF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DVHGF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DVHGF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608586408","title":"Press Release: DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT","url":"https://stock-news.laohu8.com/highlight/detail?id=2608586408","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608586408?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:45","pubTimestamp":1770039900,"startTime":"0","endTime":"0","summary":"QUBEC, Feb. 2, 2026 /CNW/ - Devonian Health Group Inc.   , a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, is pleased to announce that it has appointed Dennis Turpin as Chief Financial Officer of the Company, effective today. Mr. Turpin currently serves and will remain on the Board of Directors of the Company. Before his appointment as Chief Financial Officer, he also served as Chair of the Audit Committee, a role that will now be assumed by Mr. Pierre Labbé.Mr. Turpin is a seasoned professional executive and chartered professional accountant  with significant experience in finance, capital markets transactions, business development as well as mergers and acquisitions, over 25 years of which have been in the biopharmaceutical industry.\"I am pleased to welcome Dennis and confident that he will help strengthen our management approach, diversify our perspectives, enhance our collective expertise, and help guide the development of Devonian","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","BK4141","LU2360107325.USD","IE00BZ199S13.USD","LU1861214812.USD","LU0724618433.USD","BK4500","LU2298322129.HKD","LU1548497426.USD","BK4007","LU1861220033.SGD","BK4512","DVHGF","LU1720051017.SGD","CPA","LU2357305700.SGD","LU0348723411.USD","ON","LU1861215975.USD","LU1720051108.HKD","IE00BD6J9T35.USD","BK4585","LU0124384867.USD","LU1861219969.SGD","LU1854103824.USD","LU1236620834.HKD","LU1978683503.SGD","LU1854104046.USD","IE00BFMHRM44.USD","LU1236620750.USD","BK4588","BK4605"],"gpt_icon":0},{"id":"2590501713","title":"Press Release: Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501713","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501713?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:45","pubTimestamp":1765547100,"startTime":"0","endTime":"0","summary":"-- Company continues preclinical studies for Thykamine in MASH and. Fibrosis, furthering the understanding of Thykamine's mechanism of. -- Thykamine: A New Player in the Field of Anti-Inflammatory Drugs. -- Design for Thykamine Phase 2/3 clinical study in pediatric Atopic. Dermatitis is complete based on the positive results of the phase 2 in an. -- First quarter gross margin on distribution revenues of $0.5 million. -- First quarter net loss of $1.6 million dollars,  per share. QUBEC, Dec. 12, 2025 /CNW/ - Devonian Health Group Inc.   , today announced operating and financial results for its first quarter ended on October 31, 2025. Cream applied twice daily to pediatric patients (3 months. -- The Company is preparing its pivotal clinical study of Thykamine for. announced the appointment of Mr. Pierre Labbé as new b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4099","BK4604","BK4555","BK4007","BK4588","TM","03160","DVHGF"],"gpt_icon":0},{"id":"2586061269","title":"Press Release: Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2586061269","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586061269?lang=en_us&edition=fundamental","pubTime":"2025-11-27 01:02","pubTimestamp":1764176520,"startTime":"0","endTime":"0","summary":"-- Fourth quarter distribution revenues of $1.3 million. -- Fourth quarter net loss of $0.4 million, $0.003 per share. -- Annual net loss of $6 million, $0.041 per share. -- Devonian is debt free with $7 million in cash as of July 31, 2025. QUBEC, Nov. 26, 2025 /CNW/ - Devonian Health Group Inc.   , a biopharmaceutical corporation specializing in the development of prescription drugs targeting inflammatory diseases today announced financial results for its fourth quarter and fiscal year ended July 31, 2025.\"Our year-end results reflect a company that is financially disciplined, debt-free, and strategically positioned for the next phase of value creation. With this strong foundation, we are intensifying our efforts to advance Thykamine's added-value programs in the fibro-inflammatory space--an area where unmet medical needs remain significant. Our team is committed to executing with excellence as we continue building momentum and delivering on our long-term vision for Devonian.\" said Dr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVHGF","BK4555","BK4588","BK4604","TM","BK4099","BK4585","03160","BK4007"],"gpt_icon":0},{"id":"2577345145","title":"Press Release: Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2577345145","media":"Dow Jones","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577345145?lang=en_us&edition=fundamental","pubTime":"2025-10-23 08:02","pubTimestamp":1761177720,"startTime":"0","endTime":"0","summary":"/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/. QUEBEC, Oct. 22, 2025 /PRNewswire/ - Devonian Health Group Inc.   , a biopharmaceutical corporation specializing in the development of prescription drugs targeting inflammatory diseases today announced that Dr. André Boulet, PhD, Chairman and Chief Executive Officer, will present at the ThinkEquity Conference on Thursday, October 30, 2025.The event will bring together leading institutional investors, analysts, and growth-oriented companies for presentations and networking opportunities.-- Location: Mandarin Oriental, 80 Columbus Circle, New York City. Institutional investors interested in meeting with Devonian Health Group's management are encouraged to contact and to register on the conference website to request a meeting.All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the intended use of proceeds","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999006266.SGD","SG9999001846.SGD","BK4007","SG9999001135.SGD","BK6062","BK6515","SG9999004360.SGD","V03.SI","SG9999000475.SGD","DVHGF","SG9999008742.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DVHGF\",params:#limit:6,delay:false,,,undefined,":[]}}